Page last updated: 2024-11-12

anticapsin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

anticapsin: biologically active metabolite of Streptomyces griseoplanus; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anticapsin : An alanine derivative that is L-alanine bearing a 5-oxo-7-oxabicyclo[4.1.0]hept-2-yl substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11769495
CHEBI ID85005
MeSH IDM0040098

Synonyms (14)

Synonym
28978-07-6
anticapsin
nsc-177854
CHEBI:85005
75pq0dz8r2 ,
unii-75pq0dz8r2
nsc 177854
7-oxabicyclo(4.1.0)heptane-2-propanoic acid, alpha-amino-5-oxo-, (1r-(1alpha,2beta(s*),6alpha))-
7-oxabicyclo(4.1.0)heptane-2-propanoic acid, .alpha.-amino-5-oxo-, (.alpha.s,1r,2s,6r)-
C20941
Q27158272
7-oxabicyclo[4.1.0]heptane-2-propanoic acid, alpha-amino-5-oxo-, (alphas,1r,2s,6r)-
(2s)-2-amino-3-[(1r,2s,6r)-5-oxo-7-oxabicyclo[4.1.0]heptan-2-yl]propanoic acid
DTXSID801318391
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitorAn EC 2.6.1.* (transaminase) inhibitor that interferes with the action of glutamine--fructose-6-phosphate transaminase (isomerizing) (EC 2.6.1.19).
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitorAn EC 2.6.1.* (transaminase) inhibitor that interferes with the action of glutamine--fructose-6-phosphate transaminase (isomerizing) (EC 2.6.1.19).
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
alicyclic ketoneA cyclic ketone in which the carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
L-alanine derivativeA proteinogenic amino acid derivative resulting from reaction of L-alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-alanine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
L-alpha-amino acid zwitterionZwitterionic form of an L-alpha-amino acid having an anionic carboxy group and a protonated amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (64.29)18.7374
1990's0 (0.00)18.2507
2000's2 (14.29)29.6817
2010's3 (21.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.80 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]